IMCIVREE delivered early, significant, and sustained weight reduction1
← Swipe left or right to see all tabs →
Weight reduction in patients ≥18 years of age1
← Swipe left or right to view →

*ATB=active treatment baseline, defined as the last measurement before the first dose of IMCIVREE, ie, week 0 for IMCIVREE group and week 14 for placebo group.1
†Data shown only include patients who received 52 weeks of IMCIVREE at the time of the analysis.1
‡For patients aged 18 years or older, population sizes ranged from 7 to 15, with n=12 at 52 weeks on active treatment. Error bars are the standard deviation (SD).1
Clinically significant ~10% mean weight reduction in patients ≥18 years of age1
In patients ≥18 years old with BBS during the 14-week placebo-controlled period
13x greater weight reduction with IMCIVREE vs placebo1
Weight changes in pivotal and supplemental patients ≥18 years of age with BBS during the 14-week double-blind, placebo-controlled period*
← Swipe left or right to view →
*Supplemental patients were enrolled after the pivotal cohort had begun treatment. None of the supplemental patients had completed 52 weeks of IMCIVREE treatment at the time of data analysis.
PCPB=placebo-controlled period baseline.
Results from a long-term extension study in patients with BBS ≥18 years of age (n=6):
IMCIVREE delivered sustained and improved weight reduction at 24 months1,2*
- No new safety signals were observed during long-term administration of IMCIVREE at 24 months1
- One patient discontinued due to an adverse event unrelated to IMCIVREE1
- At completion of an index trial, 19 patients enrolled in a separate open-label, long-term extension study had received at least 24 months of IMCIVREE
- Patients to be assessed every 3 months until the end of the study (up to 5 years or patient withdrawal)
*Compared with measures at index trial baseline.2
Percentage change in weight in patients ≥18 years of age after 52 weeks (n=12)1
*Patients with data after 52 weeks of treatment.1
Patients were not required to change their diet or exercise routine1
In patients ≥18 years old with BBS during the 14-week placebo-controlled period
13x greater weight reduction with IMCIVREE vs placebo1
Weight changes in pivotal and supplemental patients ≥18 years of age with BBS during the 14-week double-blind, placebo-controlled period*
← Swipe left or right to view →
*Supplemental patients were enrolled after the pivotal cohort had begun treatment. None of the supplemental patients had completed 52 weeks of IMCIVREE treatment at the time of data analysis.
PCPB=placebo-controlled period baseline.
Results from a long-term extension study in patients with BBS ≥18 years of age (n=6):
IMCIVREE delivered sustained and improved weight reduction at 24 months1,2*
- No new safety signals were observed during long-term administration of IMCIVREE at 24 months1
- One patient discontinued due to an adverse event unrelated to IMCIVREE1
- At completion of an index trial, 19 patients enrolled in a separate open-label, long-term extension study had received at least 24 months of IMCIVREE
- Patients to be assessed every 3 months until the end of the study (up to 5 years or patient withdrawal)
*Compared with measures at index trial baseline.2